CNS Pharmaceuticals Inc (CNSP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CNS Pharmaceuticals Inc (CNSP) has a cash flow conversion efficiency ratio of -0.194x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.54 Million) by net assets ($18.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see CNSP market cap overview for the company's overall valuation and market capitalisation.
CNS Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how CNS Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
CNS Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CNS Pharmaceuticals Inc ranked by their cash flow conversion efficiency. See CNSP operating cash to total liabilities to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
VerifyMe Inc
NASDAQ:VRME
|
0.005x |
|
Batero Gold Corp
V:BAT
|
-0.003x |
|
Cazaly Resources Ltd
AU:CAZ
|
-0.048x |
|
Moatable Inc
NYSE:MTBLY
|
0.025x |
|
Pure Biologics Spólka Akcyjna
WAR:PUR
|
0.011x |
|
One Click Group Ltd
AU:1CG
|
0.181x |
|
Courtois S.A
PA:COUR
|
-0.010x |
|
Cambridge Technology Enterprises Limited
NSE:CTE
|
0.319x |
Annual Cash Flow Conversion Efficiency for CNS Pharmaceuticals Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of CNS Pharmaceuticals Inc from 2017 to 2025. View today's stock price for CNS Pharmaceuticals Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $4.52 Million | $-13.81 Million | -3.054x | -10.22% |
| 2024-12-31 | $6.18 Million | $-17.11 Million | -2.771x | -186.84% |
| 2023-12-31 | $-4.43 Million | $-14.14 Million | 3.190x | +345.76% |
| 2022-12-31 | $8.13 Million | $-10.56 Million | -1.298x | +36.50% |
| 2021-12-31 | $6.62 Million | $-13.54 Million | -2.045x | -289.68% |
| 2020-12-31 | $13.95 Million | $-7.32 Million | -0.525x | -12.23% |
| 2019-12-31 | $7.60 Million | $-3.55 Million | -0.467x | -135.85% |
| 2018-12-31 | $-549.30K | $-716.38K | 1.304x | -31.96% |
| 2017-12-31 | $-58.53K | $-112.20K | 1.917x | -- |
About CNS Pharmaceuticals Inc
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate ca… Read more